诸暨高特佳睿安投资合伙企业（有限合伙）（以下简称"诸暨高特佳"）、重庆 高特佳睿安股权投资基金合伙企业（有限合伙）（以下简称"重庆高特佳"）、杭州 高特佳睿海投资合伙企业（有限合伙）（以下简称"杭州高特佳"）、杭州睿泓投资 合伙企业（有限合伙）（以下简称" 杭州睿泓"）（诸暨高特佳、重庆高特佳、杭州 高特佳、杭州睿泓以下合称为"转让方"）保证向广州安必平医药科技股份有限公 司（以下简称"安必平""公司"）提供的信息内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 证券代码：688393 证券简称：安必平 公告编号：2025-028 广州安必平医药科技股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 1%的提示性公告 重要内容提示： 一、 转让方情况 本次询价转让的转让方诸暨高特佳、重庆高特佳、杭州高特佳、杭州睿泓 与安必平董事王海蛟为一致行动人。 注：转让方与一致行动人王海蛟询价转让前合计持有安必平股权比例为 8.73%；转让后合计持 有安必平股权比例为 6.73% (一) ...

Group 1 - Company X plans to purchase servers from multiple suppliers for a total amount not exceeding 4 billion yuan, primarily for providing computing power leasing services [1] - The transaction amount accounts for over 50% of the company's latest audited net assets and total assets, requiring approval from the shareholders' meeting [1] Group 2 - Company Y's stock has hit the limit up for four consecutive trading days, with a cumulative increase of 46.44%, indicating significant market interest in its cultural and creative business [2] - The volatility of the cultural and creative business is substantial, with projected revenues of 88.68 million yuan, 54.17 million yuan, and 184.62 million yuan for the years 2022 to 2024 respectively [2] - The main business remains focused on cigarette labels despite the fluctuations in the cultural and creative sector [2] Group 3 - Company Z's controlling shareholder is planning a change in control, intending to transfer 72.4276 million shares, representing 22.396% of the total share capital, to another investment group [3] - The stock will be suspended from trading starting May 28, 2025, for a period not exceeding two trading days [3] Group 4 - Company A has submitted an application for the issuance and listing of H-shares on the Hong Kong Stock Exchange [4] - The application materials are subject to updates and revisions as per the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [4] Group 5 - Company B's wholly-owned subsidiary plans to acquire 100% of the Czech IMI company for approximately 9.425567 million euros, aiming to enhance its global strategy and production layout [5] - The acquisition does not constitute a related party transaction or a major asset restructuring and does not require shareholder approval [5] Group 6 - Company C reported that its production costs and sales have not experienced significant fluctuations, despite its stock price deviating by over 20% in recent trading days [6] - The company confirmed that there are no undisclosed significant matters related to its operations or its controlling shareholders [6] Group 7 - Company D's stock has been trading with high volatility, with a TTM price-to-earnings ratio of 73.68, significantly above the industry median of 31.76 [7] - The company has a trading turnover rate of 19.65% as of May 27 [7] Group 8 - Company E has confirmed that its recent operational conditions and external business environment have not undergone significant changes, despite stock price fluctuations [9] - The company has no undisclosed significant matters or ongoing major plans [9] Group 9 - Company F's actual controller sold 0.26% of the company's shares during a period of stock price volatility, with proceeds partially allocated for land purchases and factory construction [10] - The actual controller may consider further stock purchases based on market conditions [10] Group 10 - Company G announced that a recent certification for its subsidiary's products will not have a direct impact on its revenue or profits [11] - The stock has also experienced significant price fluctuations recently [11] Group 11 - Company H has decided to terminate the restructuring plan for its subsidiaries due to a lack of consensus on transaction terms and changes in market conditions [12] - The decision is expected to have no adverse effects on shareholder interests [12]

证券代码：688393 证券简称：安必平 公告编号：2025-027 广州安必平医药科技股份有限公司 股东询价转让定价情况提示性公告 股东诸暨高特佳睿安投资合伙企业（有限合伙）、重庆高特佳睿安股权投 资基金合伙企业（有限合伙）、杭州高特佳睿海投资合伙企业（有限合伙）、 杭州睿泓投资合伙企业（有限合伙）保证向广州安必平医药科技股份有限公司 （以下简称"安必平"或"本公司"）提供的信息内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责 任。 （一）经向机构投资者询价后，初步确定的转让价格为24.09元/股。 （二）参与本次询价转让报价的机构投资者家数为7家，涵盖基金管理公司、 证券公司、私募基金管理人等专业机构投资者。参与本次询价转让报价的机构投资 者合计有效认购股份数量为261万股，对应的有效认购倍数为1.39倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为5家机构投 资者，拟受让股份总数为1,871,500股。 二、风险提示 （一）本次询价转让受让方及受让股数仅为初步结果，尚存在拟转让股份被司 法冻结、扣划等风险。询价转让的最终结果以中国证券登记结算有 ...

中国经济网北京5月27日讯安必平(688393.SH)昨日晚间发布股东询价转让计划书。 公告显示，拟参与本次安必平首发前股东询价转让(以下简称"本次询价转让")的股东为诸暨高特佳睿安 投资合伙企业(有限合伙)(以下简称"诸暨高特佳")、重庆高特佳睿安股权投资基金合伙企业(有限合伙) (以下简称"重庆高特佳")、杭州高特佳睿海投资合伙企业(有限合伙)(以下简称"杭州高特佳")、杭州睿泓 投资合伙企业(有限合伙)(以下简称"杭州睿泓")(诸暨高特佳、重庆高特佳、杭州高特佳、杭州睿泓以下 合称为"出让方")。 出让方拟转让股份总数为1,871,500股，占安必平总股本的比例为2.00%。其中，诸暨高特佳拟转让股份 总数为1,081,700股，占安必平总股本的比例为1.16%；重庆高特佳拟转让股份总数为404,100股，占安必 平总股本的比例为0.43%；杭州高特佳拟转让股份总数为248,500股，占安必平总股本的比例为0.27%； 杭州睿泓拟转让股份总数为137,200股，占安必平总股本的比例为0.15%。 | 床食 | 股东名称 | 拟转让股份数 | | 占总股本比 占所持股份 占一致行动人合 | | | 转让原 ...

? 拟参与本次安必平首发前股东询价转让（以下简称"本次询价转让"） 的股东为诸暨高特佳睿安投资合伙企业（有限合伙） （以下简称"诸暨高特佳"）、 证券代码：688393 证券简称：安必平 公告编号：2025-026 广州安必平医药科技股份有限公司 股东诸暨高特佳睿安投资合伙企业（有限合伙）、重庆高特佳睿安股权投资 基金合伙企业（有限合伙）、杭州高特佳睿海投资合伙企业（有限合伙）、杭州 睿泓投资合伙企业（有限合伙）保证向广州安必平医药科技股份有限公司（以下 简称"安必平"或"公司"）提供的信息内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 重庆高特佳睿安股权投资基金合伙企业（有限合伙） （以下简称"重庆高特佳"）、 杭州高特佳睿海投资合伙企业（有限合伙）（以下简称"杭州高特佳"）、杭州 睿泓投资合伙企业（有限合伙）（以下简称"杭州睿泓"）（诸暨高特佳、重庆 高特佳、杭州高特佳、杭州睿泓以下合称为"出让方"）； ? 出让方拟转让股份总数为 1,871,500 股，占安必平总股本的比 ...

华泰联合证券有限责任公司 关于广州安必平医药科技股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 （深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小镇 B7 栋 401） 华泰联合证券有限责任公司（以下简称"华泰联合证券"）受广州安必平医 药科技股份有限公司（以下简称 "安必平"）股东诸暨高特佳睿安投资合伙企业 （有限合伙）（以下简称"诸暨高特佳"）、重庆高特佳睿安股权投资基金合伙企 业（有限合伙）（以下简称"重庆高特佳"）、杭州高特佳睿海投资合伙企业（有 限合伙） （以下简称"杭州高特佳"）、杭州睿泓投资合伙企业（有限合伙） （以下 一、本次询价转让的委托 华泰联合证券收到出让方关于本次询价转让的委托，委托华泰联合证券组织 实施本次询价转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 简称" 杭州睿泓"）（诸暨高特佳、重庆高特佳、杭州高特佳、杭州睿泓以下合 称为"出让方"）委托，组织实施本次安必平首发前股东向特定机构投资者询价 转让（以下简称 "本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》 《科创 板上市公司持续监管办 ...

华泰联合证券有限责任公司 关于广州安必平医药科技股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 （深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小镇 B7 栋 401） 华泰联合证券有限责任公司（以下简称"华泰联合证券"）受广州安必平医 药科技股份有限公司（以下简称"安必平"）股东诸暨高特佳睿安投资合伙企业 （有限合伙）（以下简称"诸暨高特佳"）、重庆高特佳睿安股权投资基金合伙企 业（有限合伙）（以下简称"重庆高特佳"）、杭州高特佳睿海投资合伙企业（有 限合伙）（以下简称"杭州高特佳"）、杭州睿泓投资合伙企业（有限合伙）（以下 简称" 杭州睿泓"）（诸暨高特佳、重庆高特佳、杭州高特佳、杭州睿泓以下合 称为"出让方"）委托，组织实施本次安必平首发前股东向特定机构投资者询价 转让（以下简称 "本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上 市公司股东减持股份管理暂行办法》《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人员减持股份》《上海证券交 ...

证券代码：688393 证券简称：安必平 公告编号：2025-026 广州安必平医药科技股份有限公司 股东询价转让计划书 股东诸暨高特佳睿安投资合伙企业（有限合伙）、重庆高特佳睿安股权投资 基金合伙企业（有限合伙）、杭州高特佳睿海投资合伙企业（有限合伙）、杭州 睿泓投资合伙企业（有限合伙）保证向广州安必平医药科技股份有限公司（以下 简称"安必平"或"公司"）提供的信息内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 拟参与本次安必平首发前股东询价转让（以下简称"本次询价转让"） 的股东为诸暨高特佳睿安投资合伙企业（有限合伙）（以下简称"诸暨高特佳"）、 重庆高特佳睿安股权投资基金合伙企业（有限合伙）（以下简称"重庆高特佳"）、 杭州高特佳睿海投资合伙企业（有限合伙）（以下简称"杭州高特佳"）、杭州 睿泓投资合伙企业（有限合伙）（以下简称"杭州睿泓"）（诸暨高特佳、重庆 高特佳、杭州高特佳、杭州睿泓以下合称为"出让方"）； 出让方拟转让股份总数为 1,871,500 股，占安必平总 ...

Core Viewpoint - Anbiping (688393) reported a closing price of 29.13 yuan as of May 23, 2025, reflecting a 6.0% decrease from the previous week's price of 30.99 yuan [1] Company Announcement Summary - Anbiping announced a cash dividend distribution of 0.10 yuan per share, totaling 9,356,769.90 yuan [2] - The profit distribution plan was approved at the 2024 annual shareholders' meeting held on May 15, 2025 [2] - Key dates include: - Record date: May 28, 2025 - Ex-dividend date: May 29, 2025 - Dividend payment date: May 29, 2025 [2] - The distribution base is based on a total share capital of 93,567,699 shares [2] Tax Treatment Summary - Individual shareholders holding unrestricted circulating shares for over one year are exempt from personal income tax, receiving a net dividend of 0.10 yuan per share [2] - QFII shareholders will have a withholding tax rate of 10%, resulting in a net dividend of 0.09 yuan per share [2] - "Shanghai-Hong Kong Stock Connect" shareholders will also face a 10% withholding tax, receiving a net dividend of 0.09 yuan per share [2] - Other institutional investors and corporate shareholders will not have withholding tax, receiving a gross dividend of 0.10 yuan per share [2]

Core Viewpoint - The stock of Berry Genomics has reached its daily limit, with other companies in the sector such as Celgen, Chuangyi Huikang, Tigermed, Anbiping, Meinian Health, and BGI also experiencing gains. This surge is linked to the announcement from Insilico Medicine's CEO, Alex Zhavoronkov, regarding the potential market entry of the first drugs entirely conceived by artificial intelligence by 2030 [1] Group 1 - Berry Genomics has hit the daily trading limit, indicating strong market interest and investor confidence [1] - Other companies in the healthcare and biotechnology sector, including Celgen, Chuangyi Huikang, Tigermed, Anbiping, Meinian Health, and BGI, have also seen their stock prices rise in response to the news [1] - Insilico Medicine's CEO has projected that the first AI-conceived drugs could be available by 2030, highlighting the growing role of artificial intelligence in drug development [1]